Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Clinical Cooperation Unit Molecular Hematology/Oncology

Prof. Dr. Alwin Krämer


The Clinical Cooperation Unit Molecular Hematology/Oncology has a basic science focus on causes and consequences of chromosomal instability while its clinical/translational research centers around carcinoma of unknown primary (CUP).

Chromosomal instability is a nearly universal feature of human malignancies and a major contributor to genetic heterogeneity, clonal evolution and metastasis, themselves being at the center of cancer development, progression, relapse, and therapy resistance in solid tumors. One basic research topic focuses on how amplified centrosomes – the spindle pole organizers responsible for correct chromosome segregation during mitosis – lead to chromosomal instability. Specifically, we currently explore whether amplified centrosomes cause tumor formation in a transgenic animal model in vivo. Also, we map the landscape of centrosome aberrations in primary tumor specimens using high resolution 3D electron microscopy approaches.

In CUP syndrome, a paradigm metastatic malignancy in which only metastases but no primary tumor can be identified, we have initiated a large international, randomized phase III trial, examining the role of mutation-based targeted treatments and immunotherapy compared to standard chemotherapy. In addition, we are leading a national multicenter trial to examine the impact of immune checkpoint inhibitor combination therapy in patients with relapsed / refractory CUP syndrome.

Within the frame of these clinical trials and as a synthesis of our basic and clinical research efforts, our translational research program explores the contribution of chromosomal instability to the metastatic process and the poor prognosis of patients with CUP. Overarching goal is the development of novel treatment options in patients with metastatic disease.

The Translational Myeloma Research Group of the Heidelberg Myeloma Center focuses on molecular and pathophysiologic aspects of multiple myeloma, with special interest in mechanisms of drug resistance, spatial heterogeneity of clonal evolution, and novel therapeutic targets. Our group serves as the translational research core of the German-speaking Multiple Myeloma Study Group (GMMG) and is responsible for many correlative science projects in the context of multicenter clinical trials.


Prof. Dr. Alwin Krämer
Molecular Hematology/Oncology (A360)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg

Tel: +49-6221-42-1440 (DKFZ)
+49-6221-56-38183 (Klinik)
E-Mail: (DKFZ) (Klinik)

Selected Publications

  • Krämer A, Bochtler T, Pauli C, Baciarello G, Delorme S, Hemminki K, Mileshkin L, Moch H, Oien K, Olivier T, Patrikidou A, Wasan H, Zarkavelis G, Pentheroudakis G, Fizazi K, on behalf of the ESMO Guidelines Committee: Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. (online ahead of print) 2022.
  • Dittrich T, Köhrer S, Schorb M, Haberbosch I, Börmel M, Goldschmidt H, Müller-Tidow C, Raab MS, Hegenbart U, Schönland SO, Schwab Y, Krämer A: A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed-refractory multiple myeloma. Cell Reports Methods 2: 100322, 2022.
  • Vit G, Hirth A, Neugebauer N, Kraft B, Sigismondo G, Cazzola A, Tessmer C, Duro J, Krijgsveld J, Hofmann I, Berger M, Klüter H, Niehrs C, Nilsson J, Krämer A: Human SLFN5 and its Xenopus Laevis Ortholog Regulate Entry into Mitosis and Oocyte Meiotic Resumption. Cell Death Discovery 8: 484, 2022.
  • Ross JS, Sokol ES, Moch H, Mileshkin L, Baciarello G, Losa F, Beringer A, Thomas M, Elvin J, Ngo N, Jin DX, Krämer A: Comprehensive genomic profiling of carcinoma-of-unknown-primary-origin: retrospective molecular classification considering the CUPISCO study design. Oncologist 26: e394-e402, 2021.
to top
powered by webEdition CMS